{"schema_version":"secwatch.filing_event.v1","accession":"0001711279-26-000018","form_type":"8-K","ticker":"KRYS","cik":"0001711279","company_name":"Krystal Biotech, Inc.","filed_at":"2026-02-17T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.971353+00:00","generated_at":"2026-05-16T02:27:53.751831+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Krystal Biotech Q4 2025 product revenue $107.1M; net income $51.4M; regulatory wins for KB707, KB111","bullets":["Q4 product revenue $107.1M (up from $91.1M YoY); FY revenue $389.1M; net income $204.8M ($7.08 basic EPS) vs $89.2M prior year.","FDA granted RMAT designation to KB707 for advanced NSCLC and Fast Track to KB111 for Hailey-Hailey disease.","Positive CORAL-1 CF data: inhaled KB407 achieved 29.4%-42.1% airway cell transduction; CORAL-3 enrollment expected 1H 2026.","Cash and investments $955.9M; FY 2026 non-GAAP R&D+SG&A guidance $175-195M.","VYJUVEK has over 660 US reimbursement approvals; launched in Germany, France, Japan; Israel agreement signed."],"urls":{"canonical":"https://secwatch.observer/filing/0001711279-26-000018","json":"https://secwatch.observer/filing/0001711279-26-000018.json","markdown":"https://secwatch.observer/filing/0001711279-26-000018.md","text":"https://secwatch.observer/filing/0001711279-26-000018.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1711279/000171127926000018/0001711279-26-000018-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1711279/000171127926000018/krys-20260217.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T02:27:53.751831+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}